{"organizations": [], "uuid": "7bcab96c3a1e6b957d10384a546fbf2d62e6ad02", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/6", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/26/globe-newswire-protalix-biotherapeutics-to-hold-full-year-2017-financial-results-and-corporate-update-conference-call-on-march-6-2018.html", "country": "US", "domain_rank": 767, "title": "Protalix BioTherapeutics to Hold Full-Year 2017 Financial Results and Corporate Update Conference Call on March 6, 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.009, "site_type": "news", "published": "2018-02-26T15:00:00.000+02:00", "replies_count": 0, "uuid": "7bcab96c3a1e6b957d10384a546fbf2d62e6ad02"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/26/globe-newswire-protalix-biotherapeutics-to-hold-full-year-2017-financial-results-and-corporate-update-conference-call-on-march-6-2018.html", "ord_in_thread": 0, "title": "Protalix BioTherapeutics to Hold Full-Year 2017 Financial Results and Corporate Update Conference Call on March 6, 2018", "locations": [], "entities": {"persons": [], "locations": [{"name": "carmiel", "sentiment": "none"}, {"name": "israel", "sentiment": "none"}, {"name": "united states", "sentiment": "none"}], "organizations": [{"name": "protalix biotherapeutics", "sentiment": "negative"}, {"name": "nyse", "sentiment": "negative"}, {"name": "protalix biotherapeutics, inc.", "sentiment": "neutral"}, {"name": "company", "sentiment": "none"}, {"name": "tase", "sentiment": "none"}, {"name": "protalix biotherapeutics, inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "CARMIEL, Israel, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that it will report full-year 2017 financial results and provide a corporate update on Tuesday, March 6, 2018 at 8:30 am ET.\nTo participate in the conference call, please dial the following numbers prior to the start of the call: United States: +1-844-358-6760; International: +1-478-219-0004. Conference ID number 2636229.\nThe conference call will also be broadcast live and available for replay for two weeks on the Company’s website, www.protalix.com , in the Events Calendar of the Investors section. Please access the Company’s website at least 15 minutes ahead of the conference to register, download, and install any necessary audio software.\nAbout Protalix BioTherapeutics, Inc.\nProtalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix’s unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix’s first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. Protalix’s development pipeline includes the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; OPRX-106, an orally-delivered anti-inflammatory treatment; alidornase alfa for the treatment of Cystic Fibrosis; and others. Protalix has entered into an ex-United States partnership with Chiesi Farmaceutici S.p.A. for the development and commercialization of pegunigalsidase alfa. Protalix maintains full rights to pegunigalsidase alfa in the United States.\nInvestor Contact\nMarcy Nanus\nSolebury Trout Group\n646-378-2927\nmnanus@troutgroup.com\nSource:Protalix BioTherapeutics, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=RfkqPtsaLlzPzHlzUJJohY7Ci4UrDQd2CceEzFrQ4E5lx2OMURXRwx5Iv5W57ThgeAgiZIVZOkpbVlsi7_z_iveDaaaLv5Ur-H9jYQSUlNx2Jog-OvZO4zskvYGo3YgvKQNaphtvNrnm6Yz_1OpoHmxAbAGVcXq3jR0vO2foy2tTZ9t50jFp2mLVUT9esz-5tEGZ6yDC5HgWfR1kf8R1yNkJeABatuHZ5dN9Nd-vVYU="], "published": "2018-02-26T15:00:00.000+02:00", "crawled": "2018-02-26T17:36:50.000+02:00", "highlightTitle": ""}